Actively Recruiting
Trident Multi-tined Cannula for Cervical MBRFA Compared to the Conventional Cannula
Led by University of Utah · Updated on 2025-07-01
80
Participants Needed
3
Research Sites
183 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cervical medial branch radiofrequency ablation (CMBRFA) is an effective treatment for cervical facet pain. The efficacy of CMBRFA was proven by studies published in the late 1990's and early 2000's. Patients were selected by a strict, labor-intensive placebo-controlled, diagnostic block protocol and were treated using a conventional monopolar cannula that was positioned parallel to the medial branch, two to three lesions per medial branch nerve and both sagittal and oblique passes. Since the original CMBRFA publications, patient selection for CMBRFA is less strict, and new RFA cannulae have been developed to improve efficiency and safety while maintaining a large ablative lesion. Current clinical patient selection criteria for CMBRFA tend to be more relaxed than described in early research studies. However, subsequent research has shown that when selection criteria are too relaxed, outcomes are poorer. A recent cross-sectional study reported that when CMBRFA is done in patients selected by \>80% pain improvement after dual medial branch blocks, outcomes are similar to patients selected with a stricter selection protocol (100% pain relief) similar to the original CMBRFA studies. Although, the cross-sectional study suggests an appropriate selection criteria, it has not been used in any prospective studies. The Trident multi-tined cannula is a recent technology that produces a large ablative lesion distal to the triple-tined tip. This design allows a perpendicular/lateral approach to CMBRFA and only requires a single lesion at each medial branch. This differs from the conventional cannula, which produces it's most extensive ablative lesion along the cannula with minimal distal projection. As a result, it requires a parallel approach with multiple burn cycles at the same medial branch. The perpendicular approach with Trident and single lesion cycle at each medial branch are appealing for safety purposes and efficiency however, it's efficacy has not been directly compared to the standard conventional cannula. Problem: There are no randomized controlled trials comparing novel technologies like Trident cannula to the previously studied conventional cannula in patients selected with a more practical selection criteria. Purpose: To compared procedural characteristics, pain, and disability outcomes of CMBRFA using either a Trident or conventional cannula in patients with confirmed facet mediated pain (defined by ≥80% symptom reduction after dual medial branch block). Central Hypothesis: Trident cannula during CMBRFA will result in noninferior improvements in pain and function compared to conventional cannula but will significantly reduce procedural discomfort, time and radiation exposure. Specific Aims: 1. Determine the proportion of patients with a successful pain response (defined as ≥50% improvement in index pain) to Trident (T-CMBRFA) versus conventional (C-CMBRFA) at 3, 6, and 12 months. 2. Determine the proportion of patients with a successful functional response (defined as ≥10% reduction on neck disability index \[NDI\]) to T-CMBRFA versus C-CMBRFA at 3, 6, and 12 months. 3. Determine the proportion of patients with a successful perception of improvement (defined as a score ≥6 on the Patient Global Impression of Change \[PGIC\]) to T-CMBRFA versus C-CMBRFA at 3, 6, and 12 months.
CONDITIONS
Official Title
Trident Multi-tined Cannula for Cervical MBRFA Compared to the Conventional Cannula
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patient aged 18 or older who can understand and consent in English and comply with study procedures
- Axial (non-radicular) neck pain lasting at least 3 months
- Neck pain with an average numeric rating of 4 or greater over 7 days at baseline
- Positive response to dual diagnostic medial branch blocks at appropriate levels, with at least 1 hour relief after lidocaine and 2 hours relief after bupivacaine
You will not qualify if you...
- Receiving compensation for pain treatment such as disability, worker's compensation, or litigation
- Currently incarcerated
- Unable to read English or complete assessment tools
- Allergy to contrast media or local anesthetics
- Chronic widespread pain conditions like fibromyalgia
- Previous cervical medial branch radiofrequency neurotomy
- Severe depression or psychotic symptoms
- Possible pregnancy or any reason preventing fluoroscopy use
- Daily chronic opioid use exceeding 50 morphine equivalents
- Presence of a pacemaker or neurostimulator
- Active systemic infection at time of procedure
- Uncontrolled bleeding disorders
- Need for intravenous sedation during procedure
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
University of Utah Farmington Health Center
Farmington, Utah, United States, 84025
Actively Recruiting
2
University of Utah Orthopaedic Center
Salt Lake City, Utah, United States, 84108
Actively Recruiting
3
University of Utah South Jordan Health Center
South Jordan, Utah, United States, 84009
Actively Recruiting
Research Team
P
PMR Research Group
CONTACT
T
Taylor Burnham, DO
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here